6:11 PM
 | 
Nov 01, 2012
 |  BC Extra  |  Top Story

Vertex to evaluate all-oral HCV regimens

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced two non-exclusive deals on Thursday to evaluate all-oral HCV regimens containing Vertex's VX-135 ( ALS-2200) in Phase II studies. Vertex partnered with Johnson & Johnson (NYSE:JNJ) to evaluate VX-135 plus J&J's simeprevir ( TMC435), and with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to evaluate VX-135 and GSK2336805. The Phase II trials each will evaluate 12-week...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >